iCAD, Inc., which designs, develops and markets Computer Aided Detection (CAD) imaging technology and systems for the early detection of breast cancer and other medical applications, today announced tha
Sirna Therapeutics has announced that the United Kingdom (UK) Patent Office has granted the Company two additional short interfering RNA (siRNA) target patents. The first patent covers any siRNA with on
Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted US Patent Number 6,900,035, covering methods of manufacturing HspE7, the Company's lead product candidate
Novadaq Technologies today announced that it has been granted a patent by the United States Patent and Trademark Office for the SPY(TM) Intra-operative Imaging System (SPY System). The SPY Sys
Chromos Molecular Systems has announced that it has further expanded the patent portfolio surrounding both its ACE System and REM Technology with the issuance of four key additional patents. C
Sigma-Aldrich Corporation and Alnylam Pharmaceuticals announced today that Alnylam has granted Sigma-Aldrich a non-exclusive license to provide re
Webster University's College of Arts & Sciences is offering a graduate degree program in Patent Agency. This 36-hour master of arts program, targeted towards working professionals in the technical
Spectrum Pharmaceuticals has announced that it has received from the U.S. Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for T
BSD Medical today announced that the company has received "official notice of allowance" for a new patent that is expected to be issued by the U.S. Patent Office. The patent is being secure
GenoMed announced today that the Company has submitted its 50th provisional patent application, a major milestone in any development stage company. GenoMed has so far been awarded two patents, one for tre
U.S. Patent No. 6,821,272, granted by the U.S. Patent and Trademark Office, has broad claims related to the laser pulse technology utilized in the Waterlase(R) and Waterlase(R) MD hard and soft tissue lasers. The patent is a continuation of previously granted U.S. Patent 6,288,499, and has 111 claims, of which seven are independent. Method and apparatus claims cover the use of laser pulse technology, which allows the laser system to effectively interact with the water spray, to produce a fast, clean and precise cutting action. The scope of the patent's claims is very extensive, and not limited to only dental and medical applications.
The patented laser pulse technology is responsible for the physical shape of the laser energy pulses emitted from the laser active medium, which for BIOLASE's product is the Er,Cr:YSGG crystal. The combination of specialized laser pulses, laser wavelength and water spray technology is the critical driving factor behind the Company's proprietary Waterlase technology.
"As this advancement in our core technology demonstrates, we remain committed to the development of new innovations that will further strengthen our industry-leading position in the field of laser dentistry," said Jeffrey W. Jones, Chief Technology Officer. "This patent has method and apparatus claims covering a unique laser pulse circuitry that drives HydroPhotonic technology. Additionally, this patent is part of the Company's strategic plan to expand its intellectual property portfolio and protect its market leading Waterlase technology," continued Jones.
This patented technology has been incorporated into the Company's new Waterlase MD system, which offers variable pulse rate functionality of 10 - 50 Hz, or pulses emitted per second. Pulse rate variability provides dentists with greater functionality and flexibility to adjust the speed and quality of hard and soft tissue cutting in a broad range of dental procedures.
http://www.biolase.com/